Biogen (BSP:BIIB34) Tax Rate %

: 16.21% (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Biogen's Tax Expense for the three months ended in Jun. 2023 was R$557 Mil. Biogen's Pre-Tax Income for the three months ended in Jun. 2023 was R$3,437 Mil. Therefore, Biogen's Tax Rate % for the quarter that ended in Jun. 2023 was 16.21%.

Biogen Tax Rate % Historical Data

The historical data trend for Biogen's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Tax Rate %

24.16

16.25

19.66

3.01

17.62

Biogen Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Tax Rate %																17.07	17.23	8.99	11.57	16.21

Biogen Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Biogen's Tax Rate % for the fiscal year that ended in Dec. 2022 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2022 )	/	Pre-Tax Income (A: Dec. 2022 )
	=	3319.289	/	18840.428
	=	17.62 %

Biogen's Tax Rate % for the quarter that ended in Jun. 2023 is calculated as

Tax Rate %	=	Tax Expense (Q: Jun. 2023 )	/	Pre-Tax Income (Q: Jun. 2023 )
	=	557.205	/	3436.905
	=	16.21 %

Biogen Tax Rate % Related Terms

Thank you for viewing the detailed overview of Biogen's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines